SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Clinical trial NCT06739317 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06739317
- Sponsor
- Sun Yat-sen University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-01
- Primary completion
- 2030-12-31
- Enrollment
- 398
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.